This test is most useful if any of these apply to you.
Persistent itching later in life can sometimes be a sign of bullous pemphigoid. This autoimmune skin disease can produce patches that look like eczema or hives, and some people never develop the blisters it's named for. BP230 antibody testing can help investigate that possibility when your symptoms and skin examination suggest it.
A positive result supports the diagnosis, but it needs to fit the skin findings and other tests. A negative result leaves many cases undetected. BP230 is an established supporting test for diagnosis; its proposed uses for predicting disease severity, mouth or eye involvement, and survival are much less certain.
Your outer layer of skin is fastened to the layer beneath it by small anchoring structures. BP230 is a protein inside the deepest row of skin cells that helps connect those structures to the cell's internal framework. It's also called bullous pemphigoid antigen 1 or BPAG1.
This test measures the IgG class of antibodies against BP230 in serum obtained from a blood draw. Serum is the liquid left after blood clots. The assay uses ELISA to detect antibody binding to selected pieces of BP230 and report the strength of that response. It measures circulating antibodies, while a skin biopsy can show antibodies deposited in the skin.
BP180 spans the skin cell surface. BP230 sits inside the cell, where circulating antibodies have less access. One explanation for BP230 antibodies is that an immune attack against BP180 damages the anchoring area and exposes additional targets. This expansion of an immune response is called epitope spreading, and human studies have documented it in pemphigoid. It isn't a proven sequence in every case, and the exact contribution of BP230 antibodies to blister formation remains unsettled.
BP230 testing misses a substantial share of cases. Positive results are more useful when pemphigoid is already suspected from your symptoms and examination. The performance also varies with the assay and the people being tested.
| Who Was Studied | What Was Compared | What They Found |
|---|---|---|
| 1,125 people evaluated for suspected pemphigoid at a Dutch referral center | Serum BP230 and BP180 ELISAs; BP230 results were available for 774 participants | BP230 was positive in 44.6% of confirmed cases, compared with 70.0% for BP180 |
| 313 people with pemphigoid and 488 controls | A commercial BP230 ELISA in people with and without the disease | Positive in 59.0% of cases and negative in 99.2% of controls |
| A clinical series including 170 people with pemphigoid | BP230 ELISA alone and combined with BP180 | BP230 detected 48% of cases and was negative in 94% of controls; combining both antibodies detected 66% of cases |
These percentages describe study groups. They aren't the probability that you have pemphigoid after a positive result. That depends on how likely the disease was before testing, including the appearance of your skin and other possible explanations for the rash.
BP230 can identify some cases missed by BP180 testing. The additional yield varies between studies, so there isn't a fixed percentage that applies to everyone.
In the Dutch referral study, about one in five people diagnosed with pemphigoid had no blisters. Reactivity to BP230 alone was associated with this nonbullous form and with negative biopsy staining. That makes BP230 a useful supporting clue in selected cases of persistent itching or eczema-like patches, but an isolated positive result still needs corroborating evidence.
Bullous pemphigoid is associated with neurological disease. In a German cohort of 273 people with pemphigoid, BP230 positivity was more frequent among those who also had neurological or psychiatric conditions. Among those with available antibody results, about two-thirds with these conditions were positive, compared with roughly one-third without them.
The association persisted after adjustment for other measured factors. One hypothesis involves an immune response to related proteins in nerve tissue and skin, but the study didn't establish that mechanism. These findings concern people who already had pemphigoid and don't establish BP230 testing as a way to diagnose or predict a neurological disorder.
In a French study of 95 people with bullous pemphigoid, a negative BP230 result was associated with involvement of the mouth or other moist linings. After adjustment for other factors, the odds were about eight times higher. This was an association within a small group with established disease, not a validated way to predict whether your mouth or eyes will be affected.
Mucous membrane pemphigoid is a related disorder that mainly affects these linings. In another study, BP230 IgG was detected in 53% of people with bullous pemphigoid and 11% with mucous membrane pemphigoid. There was enough overlap that this antibody alone couldn't distinguish the two conditions. The distribution of symptoms and biopsy findings remain central.
A Chinese study of 215 people also found that younger-onset bullous pemphigoid could be more severe despite lower BP230 IgG levels. These findings argue against treating a low result as evidence of mild disease or using a positive result to assume that the disease will stay confined to your skin.
A study of 143 participants from the 253-person BLISTER treatment trial found BP230 antibodies more often in older people. Higher levels were associated with a lower Karnofsky score. That score rates how well a person manages everyday activities and how much help they need.
That study linked higher BP180 levels to mortality, but didn't find the same association for BP230. A separate retrospective Italian study of 572 people did find an association between BP230 and mortality after adjustment for other factors. Its combined prediction model included age, other illnesses, treatment, severity, and both antibodies, and needs validation in an independent population. BP230 alone doesn't provide a dependable estimate of your survival.
BP230 IgG is an inconsistent measure of how active pemphigoid is. In a study of 95 people, its level didn't correlate with either of two clinical severity scores, while BP180 did. A smaller study of 27 people found a correlation for BP230, but the larger studies and follow-up data don't support using it alone to measure disease activity or predict relapse.
Research on BP230 IgE concerns a different antibody class from the IgG measured here. In a study that tested 154 serum samples, the finding during follow-up came from only seven people with detectable BP230 IgE: their levels followed disease activity over time. Across the larger group, IgE levels weren't correlated with disease activity.
A separate small study found BP230 IgE in 59.5% of people whose pemphigoid resisted topical steroid treatment, with antibodies often targeting a different part of the protein. These findings can't be used to interpret a BP230 IgG result or predict whether steroid creams will work for you.
A fall in BP230 can accompany improvement during treatment, but the number may remain positive after your skin improves or fail to change when symptoms worsen. Clinical assessment of itching, new blisters, and healing is the basis of follow-up. BP180 levels can add useful information when they were elevated at diagnosis, although they also don't replace examination.
Evidence-backed interventions that affect your Bullous Pemphigoid BP230 Antibody level
Bullous Pemphigoid BP230 Antibody is best interpreted alongside these tests.